SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on June 7, 2002; DOI 10.1182/blood-2002-02-0634. This Article Full Text Full Text (PDF) All Versions of this Article: 2002-02-0634v1 100/6/1989    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Ng, A. K. Articles by Mauch, P. M. Search for Related Content PubMed PubMed Citation Articles by Ng, A. K. Articles by Mauch, P. M. Related Collections Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 September 2002, Vol. 100, No. 6, pp. 1989-1996 CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors Andrea K. Ng, M. V. Patricia Bernardo, Edie Weller, Kendall Backstrand, Barbara Silver, Karen C. Marcus, Nancy J. Tarbell, Mary Ann Stevenson, Jonathan W. Friedberg, and Peter M. Mauch From the Department of Radiation Oncology and the Department of Medicine, Brigham and Women's Hospital; Children's Hospital; Beth Israel Deaconess Medical Center; Massachusetts General Hospital; Department of Biostatistical Sciences and Department of Adult Oncology, Dana-Farber Cancer Institute; Harvard Medical School; Boston, MA. The excess risk of second malignancy after Hodgkin disease is an increasing problem. In light of the long-term data, guidelines for follow-up of survivors of Hodgkin disease need to be redefined. In this study we attempt to analyze the long-term risks and temporal trends, identify patient- and treatment-related risk factors, and determine the prognosis of patients who develop a second malignancy after radiation treatment with or without chemotherapy for Hodgkin disease. Among 1319 patients with clinical stage I-IV Hodgkin disease, 181 second malignancies and 18 third malignancies were observed. With a median follow-up of 12 years, the relative risk (RR) and absolute excess risk of second malignancy were 4.6 and 89.3/10 000 person-years. The RR was significantly higher with combined chemotherapy and radiation therapy (6.1) than with radiation therapy alone (4.0, P = .015). The risk increased with increasing radiation field size (P = .03) in patients who received combined modality therapy, and with time after Hodgkin disease. After 15 and 20 years, there was a 2.3% and 4.0% excess risk of second malignancy per person per year. The 5-year survival after development of a second malignancy was 38.1%, with the worst prognosis seen after acute leukemia and lung cancer. The excess risk of second malignancy after Hodgkin disease continues to be increased after 15 to 20 years, and there does not appear to be a plateau. Our analysis suggests that the risk may be reduced with smaller radiation fields, as are used in current trials of abbreviated chemotherapy and limited-field radiation therapy. © 2002 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. Crump and D. Hodgson Secondary Breast Cancer in Hodgkin's Lymphoma Survivors J. Clin. Oncol., September 10, 2009; 27(26): 4229 - 4231. [Full Text] [PDF] K. C. Oeffinger, J. S. Ford, C. S. Moskowitz, L. R. Diller, M. M. Hudson, J. F. Chou, S. M. Smith, A. C. Mertens, T. O. Henderson, D. L. Friedman, et al. Breast Cancer Surveillance Practices Among Women Previously Treated With Chest Radiation for a Childhood Cancer JAMA, January 28, 2009; 301(4): 404 - 414. [Abstract] [Full Text] [PDF] K. A. Goodman, E. Riedel, V. Serrano, S. Gulati, C. H. Moskowitz, and J. Yahalom Long-Term Effects of High-Dose Chemotherapy and Radiation for Relapsed and Refractory Hodgkin's Lymphoma J. Clin. Oncol., November 10, 2008; 26(32): 5240 - 5247. [Abstract] [Full Text] [PDF] W. Landier and S. Bhatia Cancer Survivorship: A Pediatric Perspective Oncologist, November 1, 2008; 13(11): 1181 - 1192. [Abstract] [Full Text] [PDF] E. C. Bluhm, C. Ronckers, R. J. Hayashi, J. P. Neglia, A. C. Mertens, M. Stovall, A. T. Meadows, P. A. Mitby, J. A. Whitton, S. Hammond, et al. Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study Blood, April 15, 2008; 111(8): 4014 - 4021. [Abstract] [Full Text] [PDF] J. W. Friedberg Secondary malignancies after therapy of indolent non-Hodgkin's lymphoma Haematologica, March 1, 2008; 93(3): 336 - 338. [Full Text] [PDF] A. K. Ng Second Cancers after Hodgkin's Lymphoma: Long-term Risks ASCO Educational Book, January 1, 2008; 2008(1): 418 - 422. [Abstract] [Full Text] [PDF] C. Ferme, H. Eghbali, J. H. Meerwaldt, C. Rieux, J. Bosq, F. Berger, T. Girinsky, P. Brice, M. B. van't Veer, J. A. Walewski, et al. Chemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin's Disease N. Engl. J. Med., November 8, 2007; 357(19): 1916 - 1927. [Abstract] [Full Text] [PDF] M. Maule, G. Scelo, G. Pastore, P. Brennan, K. Hemminki, E. Tracey, R. Sankila, E. Weiderpass, J. H. Olsen, M. L. McBride, et al. Risk of Second Malignant Neoplasms After Childhood Leukemia and Lymphoma: An International Study J Natl Cancer Inst, May 16, 2007; 99(10): 790 - 800. [Abstract] [Full Text] [PDF] D. C. Hodgson, E. S. Gilbert, G. M. Dores, S. J. Schonfeld, C. F. Lynch, H. Storm, P. Hall, F. Langmark, E. Pukkala, M. Andersson, et al. Long-Term Solid Cancer Risk Among 5-Year Survivors of Hodgkin's Lymphoma J. Clin. Oncol., April 20, 2007; 25(12): 1489 - 1497. [Abstract] [Full Text] [PDF] B Klimm, H. Eich, H Haverkamp, A Lohri, P Koch, F Boissevain, G Trenn, P Worst, E Duhmke, R. Muller, et al. Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group Ann. Onc., February 1, 2007; 18(2): 357 - 363. [Abstract] [Full Text] [PDF] L. Arcaini, S. Burcheri, A. Rossi, C. Pascutto, F. Passamonti, E. Brusamolino, M. Paulli, E. Orlandi, M. Buelli, P. Viero, et al. Risk of Second Cancer in Nongastric Marginal Zone B-Cell Lymphomas of Mucosa-Associated Lymphoid Tissue: A Population-Based Study from Northern Italy Clin. Cancer Res., January 1, 2007; 13(1): 182 - 186. [Abstract] [Full Text] [PDF] A. Ng and P. Mauch The impact of treatment on the risk of second malignancy after Hodgkin's disease Ann. Onc., December 1, 2006; 17(12): 1727 - 1729. [Full Text] [PDF] J Franklin, A Pluetschow, M Paus, L Specht, A-P Anselmo, A Aviles, G Biti, T Bogatyreva, G Bonadonna, C Brillant, et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials Ann. Onc., December 1, 2006; 17(12): 1749 - 1760. [Abstract] [Full Text] [PDF] L. B. Travis The Epidemiology of Second Primary Cancers Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2020 - 2026. [Abstract] [Full Text] [PDF] E. Brusamolino, A. Baio, E. Orlandi, L. Arcaini, F. Passamonti, V. Griva, W. Casagrande, C. Pascutto, P. Franchini, and M. Lazzarino Long-term Events in Adult Patients with Clinical Stage IA-IIA Nonbulky Hodgkin's Lymphoma Treated with Four Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Adjuvant Radiotherapy: A Single-Institution 15-Year Follow-up. Clin. Cancer Res., November 1, 2006; 12(21): 6487 - 6493. [Abstract] [Full Text] [PDF] M. Kalaycio, L. Rybicki, B. Pohlman, R. Sobecks, S. Andresen, E. Kuczkowski, and B. Bolwell Risk Factors Before Autologous Stem-Cell Transplantation for Lymphoma Predict for Secondary Myelodysplasia and Acute Myelogenous Leukemia J. Clin. Oncol., August 1, 2006; 24(22): 3604 - 3610. [Abstract] [Full Text] [PDF] P. Das, A. K. Ng, C. C. Earle, P. M. Mauch, and K. M. Kuntz Computed tomography screening for lung cancer in Hodgkin's lymphoma survivors: decision analysis and cost-effectiveness analysis Ann. Onc., May 1, 2006; 17(5): 785 - 793. [Abstract] [Full Text] [PDF] B. F. Koontz, J. P. Kirkpatrick, R. W. Clough, R. G. Prosnitz, J. P. Gockerman, J. O. Moore, and L. R. Prosnitz Combined-Modality Therapy Versus Radiotherapy Alone for Treatment of Early-Stage Hodgkin's Disease: Cure Balanced Against Complications J. Clin. Oncol., February 1, 2006; 24(4): 605 - 611. [Abstract] [Full Text] [PDF] L. B. Travis, C. S. Rabkin, L. M. Brown, J. M. Allan, B. P. Alter, C. B. Ambrosone, C. B. Begg, N. Caporaso, S. Chanock, A. DeMichele, et al. Cancer Survivorship--Genetic Susceptibility and Second Primary Cancers: Research Strategies and Recommendations J Natl Cancer Inst, January 4, 2006; 98(1): 15 - 25. [Abstract] [Full Text] [PDF] D. L. Forrest, D. E. Hogge, T. J. Nevill, S. H. Nantel, M. J. Barnett, J. D. Shepherd, H. J. Sutherland, C. L. Toze, C. A. Smith, J. C. Lavoie, et al. High-Dose Therapy and Autologous Hematopoietic Stem-Cell Transplantation Does Not Increase the Risk of Second Neoplasms for Patients With Hodgkin's Lymphoma: A Comparison of Conventional Therapy Alone Versus Conventional Therapy Followed by Autologous Hematopoietic Stem-Cell Transplantation J. Clin. Oncol., November 1, 2005; 23(31): 7994 - 8002. [Abstract] [Full Text] [PDF] L. B. Travis, D. Hill, G. M. Dores, M. Gospodarowicz, F. E. van Leeuwen, E. Holowaty, B. Glimelius, M. Andersson, E. Pukkala, C. F. Lynch, et al. Cumulative Absolute Breast Cancer Risk for Young Women Treated for Hodgkin Lymphoma J Natl Cancer Inst, October 5, 2005; 97(19): 1428 - 1437. [Abstract] [Full Text] [PDF] J. M. Connors State-of-the-Art Therapeutics: Hodgkin's Lymphoma J. Clin. Oncol., September 10, 2005; 23(26): 6400 - 6408. [Abstract] [Full Text] [PDF] R. M. Meyer, M. K. Gospodarowicz, J. M. Connors, R. G. Pearcey, A. Bezjak, W. A. Wells, B. F. Burns, J. N. Winter, S. J. Horning, A. R. Dar, et al. Randomized Comparison of ABVD Chemotherapy With a Strategy That Includes Radiation Therapy in Patients With Limited-Stage Hodgkin's Lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group J. Clin. Oncol., July 20, 2005; 23(21): 4634 - 4642. [Abstract] [Full Text] [PDF] G. P. Canellos Chemotherapy Alone for Early Hodgkin's Lymphoma: An Emerging Option J. Clin. Oncol., July 20, 2005; 23(21): 4574 - 4576. [Full Text] [PDF] P. Das, A. K. Ng, M. A. Stevenson, and P. M. Mauch Clinical course of thoracic cancers in Hodgkin's disease survivors Ann. Onc., May 1, 2005; 16(5): 793 - 797. [Abstract] [Full Text] [PDF] L. Pagano, A. Pulsoni, M. Vignetti, M. E. Tosti, P. Falcucci, P. Fazi, L. Fianchi, A. Levis, A. Bosi, E. Angelucci, et al. Secondary acute myeloid leukaemia: results of conventional treatments. Experience of GIMEMA trials Ann. Onc., February 1, 2005; 16(2): 228 - 233. [Abstract] [Full Text] [PDF] J. M. Connors Evolving Approaches to Primary Treatment of Hodgkin Lymphoma Hematology, January 1, 2005; 2005(1): 239 - 244. [Abstract] [Full Text] [PDF] S. Bhatia Cancer Survivorship--Pediatric Issues Hematology, January 1, 2005; 2005(1): 507 - 515. [Abstract] [Full Text] [PDF] A. Tichelli and G. Socie Considerations for Adult Cancer Survivors Hematology, January 1, 2005; 2005(1): 516 - 522. [Abstract] [Full Text] [PDF] L. B. Kenney, Y. Yasui, P. D. Inskip, S. Hammond, J. P. Neglia, A. C. Mertens, A. T. Meadows, D. Friedman, L. L. Robison, and L. Diller Breast Cancer after Childhood Cancer: A Report from the Childhood Cancer Survivor Study Ann Intern Med, October 19, 2004; 141(8): 590 - 597. [Abstract] [Full Text] [PDF] K. Behringer, A. Josting, P. Schiller, H. T. Eich, H. Bredenfeld, V. Diehl, and A. Engert Solid tumors in patients treated for Hodgkin's disease: a report from the German Hodgkin Lymphoma Study Group Ann. Onc., July 1, 2004; 15(7): 1079 - 1085. [Abstract] [Full Text] [PDF] K. C. Oeffinger and M. M. Hudson Long-term Complications Following Childhood and Adolescent Cancer: Foundations for Providing Risk-based Health Care for Survivors CA Cancer J Clin, July 1, 2004; 54(4): 208 - 236. [Abstract] [Full Text] [PDF] W. Kern, T. Haferlach, S. Schnittger, W. Hiddemann, and C. Schoch Prognosis in Therapy-Related Acute Myeloid Leukemia and Impact of Karyotype J. Clin. Oncol., June 15, 2004; 22(12): 2510 - 2511. [Full Text] [PDF] R. E. Schwarz and R. K. Strair Complications of Malignancy: CASE 2. Infectious Tissue Pneumatosis As a Result of Colon Cancer Perforation in a Survivor of Hodgkin's Disease J. Clin. Oncol., January 15, 2004; 22(2): 373 - 374. [Full Text] [PDF] R. M. Meyer, R. F. Ambinder, and S. Stroobants Hodgkin's Lymphoma: Evolving Concepts with Implications for Practice Hematology, January 1, 2004; 2004(1): 184 - 202. [Abstract] [Full Text] [PDF] C. l. Maignan, B. Desablens, V. Delwail, M. Dib, C. Berthou, M. Vigier, C. Ghandour, S. Atmani, P. Casassus, H. Maisonneuve, et al. Three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or epirubicin, bleomycin, vinblastine, and methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin disease: 10-year results of a randomized trial Blood, January 1, 2004; 103(1): 58 - 66. [Abstract] [Full Text] [PDF] K. E. Nichols, J. A. Heath, D. Friedman, J. A. Biegel, A. Ganguly, P. Mauch, and L. Diller TP53, BRCA1, and BRCA2 Tumor Suppressor Genes Are Not Commonly Mutated in Survivors of Hodgkin's Disease With Second Primary Neoplasms J. Clin. Oncol., December 15, 2003; 21(24): 4505 - 4509. [Abstract] [Full Text] [PDF] J. W. Friedberg and V. Chengazi PET Scans in the Staging of Lymphoma: Current Status Oncologist, October 1, 2003; 8(5): 438 - 447. [Abstract] [Full Text] [PDF] A. Josting, S. Wiedenmann, J. Franklin, M. May, M. Sieber, J. Wolf, A. Engert, and V. Diehl Secondary Myeloid Leukemia and Myelodysplastic Syndromes in Patients Treated for Hodgkin's Disease: A Report From the German Hodgkin's Lymphoma Study Group J. Clin. Oncol., September 15, 2003; 21(18): 3440 - 3446. [Abstract] [Full Text] [PDF] J. Yahalom Breast Cancer After Hodgkin Disease: Hope for a Safer Cure JAMA, July 23, 2003; 290(4): 529 - 531. [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020